# EDGAR Filing Document

**Accession Number:** 0001075880
**File Stem:** 0001213900-26-034709
**Filing Date:** 2026-3
**Character Count:** 2546
**Document Hash:** dda070e4bafda655e86358bb5a47ff1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-034709.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001213900-26-034709

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KAZIA THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001075880
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THREE INTERNATIONAL TOWERS LEVEL 24,
- **STREET 2:** 300 BARANGAROO AVENUE
- **CITY:** SYDNEY NSW
- **PROVINCE COUNTRY:** C3
- **ZIP:** 2000
- **BUSINESS PHONE:** 01161298780088

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THREE INTERNATIONAL TOWERS LEVEL 24,
- **STREET 2:** 300 BARANGAROO AVENUE
- **CITY:** SYDNEY NSW
- **PROVINCE COUNTRY:** C3
- **ZIP:** 2000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVOGEN LTD
- **DATE OF NAME CHANGE:** 19981228

March 26, 2026

Securities and Exchange Commission

100 F. Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Kazia Therapeutics Ltd. ("Company")** |
|  | **Registration Statement on Form F-3** |
|  | **<u>File No. 333-294392</u>** |

---

<u>VIA EDGAR</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Kazia Therapeutics Limited (the "Company") hereby requests that the effective date of the above-referenced registration statement (the "Registration Statement") be accelerated to March 27, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Lucosky Brookman LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Sebastian A. Bacon of Lucosky Brookman LLP at (732) 510-5382.

Sincerely,

---

| | |
|:---|:---|
| **KAZIA THERAPEUTICS LIMITED** | **KAZIA THERAPEUTICS LIMITED** |
| By: | */s/ John Friend* |
| Name: | John Friend |
| Title: | Chief Executive Officer and Director |

---

cc: John Friend, Chief Executive Officer and Director, *Kazia Therapeutics Limited* <br> Sebastian A. Bacon, Esq., *Lucosky Brookman LLP*